CYP2C19*17 protects against metabolic complications of clozapine treatment.

  title={CYP2C19*17 protects against metabolic complications of clozapine treatment.},
  author={Irina Piatkov and Dorgival Caetano and Yolinda Assur and Sue Lynn Lau and Micheline Coelho and Trudi Jones and Tristan Nguyen and Steven C. Boyages and Mark McLean},
  journal={The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry},
  volume={18 7},
OBJECTIVES Clozapine (CZ) is the most effective drug for managing treatment-resistant schizophrenic disorders. Its use has been limited due to adverse effects, which include weight gain and new-onset diabetes, but the incidence of these varies between patients. METHODS We investigated 187 Clozapine Clinic patients (of whom 137 consented for genotyping) for the presence of CYP2C19*17 and its association with CZ and norclozapine (NCZ) levels, and clinical outcomes. RESULTS Thirty-nine percent… CONTINUE READING


Publications citing this paper.


Publications referenced by this paper.
Showing 1-10 of 53 references

neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

  • J Nielsen, P Damkier, H Lublin, D. Taylor
  • Acta psychiatrica Scandinavica. Jun;123:411-422
  • 2011
Highly Influential
2 Excerpts

CYP2C19 Polymorphisms in Patients with Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency

  • M Humbert-Claude, E Davenas, F Gbahou, L Vincent, JM. Arrang
  • Acta chimica Slovenica.63:33-37. Hepburn K…
  • 2016

Similar Papers

Loading similar papers…